<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05017246</url>
  </required_header>
  <id_info>
    <org_study_id>202105007</org_study_id>
    <nct_id>NCT05017246</nct_id>
  </id_info>
  <brief_title>Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural Anesthesia With Postoperative PCA for Patients Undergoing Exploratory Laparotomy</brief_title>
  <official_title>A Randomized Trial Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural Anesthesia With Postoperative PCA for Patients Undergoing Exploratory Laparotomy on the Gynecologic Oncology Service.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Foundation for Barnes-Jewish Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if opioid consumption postoperatively among patients undergoing non-emergent&#xD;
      laparotomy by the gynecologic oncology service who receive intrathecal morphine with&#xD;
      intraoperative lidocaine (IML) infusion are lower than patients who have epidural anesthesia&#xD;
      with PCA (EPCA).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morphine milligram equivalent (MME) in the postoperative hospital course</measure>
    <time_frame>Postoperatively while patient is in hospital (estimated to be 4 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of postoperative ileus</measure>
    <time_frame>Postoperatively while patient is in hospital (estimated to be 4 days)</time_frame>
    <description>-Defined by bilious emesis requiring a change in diet to nothing-per-mouth (NPO) status or nasogastric tube placement (NGT) in the absence of other indications. Patients who had NGT placed prophylactically at the time of surgery were not considered to have an ileus unless an NGT was reinserted or they met the above criteria. Participants will be assigned a value of yes ileus or no ileus. The rate of post op ileus is defined as the observed number of yes ileus in each study arm divided by the total number of subjects in the study arm. Fisher's exact test will be used to compare non-paired nominal data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Estimated to be 4 days</time_frame>
    <description>-Length of stay will be determined by the dates of admission as recorded on EPIC (days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of postoperative hypotension</measure>
    <time_frame>Up to 48 hours after surgery</time_frame>
    <description>-Postoperative hypotension will be defined as &lt;90/50 (as previously defined by Huepenbecker, et al.) or a 20% decrease from the preoperative office visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction with pain control</measure>
    <time_frame>Day of hospital discharge (estimated to be day 4)</time_frame>
    <description>-Patients will be asked on day of discharge if they were satisfied with their pain control during their hospitalization. They will be able to choose from the following: 0=satisfied, 1= somewhat satisfied, 2= neutral, 3=somewhat dissatisfied, 4=dissatisfied).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain scores</measure>
    <time_frame>Preoperative, each post-operative day while inpatient, 2 week follow-up, and 6 week follow-up</time_frame>
    <description>-Pain scores will be determined by the 0-10 numeric rating scale (NRS). 0=no pain and 10=the most pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 day readmission rate</measure>
    <time_frame>Through day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of deep vein thrombosis (DVT)</measure>
    <time_frame>From day of surgery (day 1) to 6 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of pulmonary thromboembolism (PTE)</measure>
    <time_frame>From day of surgery (day 1) to 6 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of persistent pain</measure>
    <time_frame>At 6 week follow-up</time_frame>
    <description>-As determined by an NRS pain score ≥ 5</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Cancer Debulking</condition>
  <condition>Enlarged Uterus</condition>
  <condition>Fibroid Uterus</condition>
  <condition>Adnexal Mass</condition>
  <arm_group>
    <arm_group_label>Epidural bupivacaine with hydromorphone patient-controlled anesthesia (EPCA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care at Washington University School of Medicine/Barnes-Jewish Hospital&#xD;
Day of surgery: preoperative tylenol, gabapentin, celebrex, and epidural dosing per standard protocol.&#xD;
Intraoperative: dexamethasone and epidural bupivacaine&#xD;
Day of surgery postoperative: hydromorphone PCA, toradol, ibuprofen, tylenol, epidural bupivacaine&#xD;
Postoperative: hydromorphone PCA, ibuprofen, oxycodone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intrathecal morphine with intraoperative lidocaine infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day or surgery: tylenol, gabapentin, celebrex, and preoperative intrathecal morphine one time injection (150mcg)&#xD;
Intraoperative: dexamethasone and lidocaine infusion 1 mg/kg ideal body weight&#xD;
Day of surgery postoperative: toradol, ibuprofen, tylenol&#xD;
Postoperative: ibuprofen, oxycodone, and hydromorphone prn</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>-Epidural bupivacaine 0.1% 2-6ml/hr based on MAP within 10% of patient's baseline MAP</description>
    <arm_group_label>Epidural bupivacaine with hydromorphone patient-controlled anesthesia (EPCA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>-Preservative-free intrathecal morphine (duramorph) 150mcg injection (0.15ml or a 0.5mg/0.5ml prepared solution)</description>
    <arm_group_label>Intrathecal morphine with intraoperative lidocaine infusion</arm_group_label>
    <other_name>Duramorph</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>-Lidocaine infusion 1 mg/kg ideal body weight (IBW)</description>
    <arm_group_label>Intrathecal morphine with intraoperative lidocaine infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients ≥18 years old&#xD;
&#xD;
          -  Undergoing non-emergent exploratory laparotomy with the Gynecologic Oncology service&#xD;
&#xD;
          -  No clinical or laboratory evidence of end organ failure:&#xD;
&#xD;
        If available:&#xD;
&#xD;
          -  Platelets &gt; 100&#xD;
&#xD;
          -  Hemoglobin &gt; 8.0&#xD;
&#xD;
          -  Serum creatinine &lt;1.5&#xD;
&#xD;
          -  INR &lt;1.3&#xD;
&#xD;
          -  All other lab values obtained as part of general preoperative work-up must be ≤1.5x&#xD;
             normal laboratory value.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients not giving consent to participate in the study&#xD;
&#xD;
          -  Unable to complete self-report pain questionnaire&#xD;
&#xD;
          -  Moderate to severe kidney or liver failure per lab criteria as outlined&#xD;
&#xD;
          -  Current treatment with anticoagulant drugs or inability to hold anticoagulant&#xD;
             medications for a safe amount of time per current ASRA guidelines&#xD;
&#xD;
          -  Contraindication to lumbar puncture or epidural placement, per acute pain management&#xD;
             service such as known coagulopathy or history of clotting disorders, history of&#xD;
             scoliosis or lumbar fusion, infection at site of entry, or current systemic infection&#xD;
&#xD;
          -  Complete bowel obstruction&#xD;
&#xD;
          -  Contraindication to intravenous lidocaine&#xD;
&#xD;
          -  No known pregnancy and not lactating.&#xD;
&#xD;
          -  Currently septic&#xD;
&#xD;
          -  Patient currently taking more than 30 MME a day preoperatively (for &gt;30 days)&#xD;
&#xD;
          -  BMI &gt;50kg/m2&#xD;
&#xD;
          -  Intolerance or contraindication to receiving non-steroidal anti-inflammatory drugs or&#xD;
             acetaminophen&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael D Toboni, M.D., MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael D Toboni, M.D., MPH</last_name>
    <phone>314-273-1905</phone>
    <email>mdtoboni@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael D Toboni, M.D., MPH</last_name>
      <phone>314-273-1905</phone>
      <email>mdtoboni@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Michael D Toboni, M.D., MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lindsay Kuroki, M.D., MSCI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lara Crock, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ERAS</keyword>
  <keyword>Multi-modal anesthesia</keyword>
  <keyword>Opioid consumption</keyword>
  <keyword>Intrathecal</keyword>
  <keyword>Epidural</keyword>
  <keyword>Ileus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

